Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. August 2026 09:07 ET | Quelle: Alembic Therapeutics

Alembic Therapeutics LLC Announces Availability of Ciprofloxacin Otic Solution 0.2%

BEDMINSTER, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Alembic Therapeutics LLC announces the U.S. availability of Ciprofloxacin Otic Solution 0.2%, an FDA-approved, AB-rated, quinolone antimicrobial...
15. Juli 2026 09:07 ET | Quelle: Alembic Therapeutics

Alembic Therapeutics LLC Announces Exclusive U.S. Distribution of NUVESSA® (metronidazole vaginal gel 1.3%)

Alembic Therapeutics LLC Announces Exclusive U.S. Distribution of NUVESSA® (metronidazole vaginal gel 1.3%)
09. Juni 2026 09:07 ET | Quelle: Alembic Therapeutics

Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.

Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
18. Februar 2026 08:03 ET | Quelle: Alembic Therapeutics

Alembic Therapeutics LLC Announces the Launch of PIVYA® (pivmecillinam)

Pivya® (pivmecillinam) Tablets, 185mg Now Available by Prescription in the United States BEDMINSTER, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Alembic Therapeutics is pleased to announce the U.S....